Cullinan Oncology is expected to report a Q3 2026 net loss per share of $0.79 on zero revenue, with its current $14.54 share price trading significantly below the $35.70 average analyst price target.
Investors are primarily focused on pipeline updates for CLN-978, a CD19 T-cell engager being evaluated for systemic lupus erythematosus (SLE) and other autoimmune conditions.
The company recently received FDA clearance to expand trials into rheumatoid arthritis and idiopathic thrombocytopenic purpura, signaling a strategic shift toward immunology.
Management is also expected to provide updates on its cash runway, which is currently projected to extend into 2029 following a successful $280 million capital raise earlier in the year.